Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) was the target of a significant decline in short interest in February. As of February 28th, there was short interest totalling 2,120,000 shares, a decline of 7.4% from the February 13th total of 2,290,000 shares. Based on an average daily trading volume, of 212,000 shares, the days-to-cover ratio is currently 10.0 days. Currently, 8.9% of the shares of the stock are sold short.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of IPSC. UBS Group AG bought a new position in Century Therapeutics during the 4th quarter valued at approximately $28,000. Barclays PLC raised its position in Century Therapeutics by 533.3% during the 4th quarter. Barclays PLC now owns 5,408 shares of the company’s stock valued at $28,000 after purchasing an additional 4,554 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Century Therapeutics by 27.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 4,157 shares of the company’s stock valued at $41,000 after purchasing an additional 904 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Century Therapeutics during the 4th quarter valued at approximately $41,000. Finally, SG Americas Securities LLC bought a new position in Century Therapeutics during the 4th quarter valued at approximately $53,000. Institutional investors own 35.81% of the company’s stock.
Century Therapeutics Trading Down 1.2 %
Shares of IPSC stock opened at $3.98 on Friday. The stock has a market capitalization of $234.70 million, a PE ratio of -2.02 and a beta of 0.69. Century Therapeutics has a 1-year low of $3.54 and a 1-year high of $14.02. The business has a 50-day moving average of $4.55 and a 200 day moving average of $7.74. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.44 and a quick ratio of 13.44.
Analysts Set New Price Targets
Century Therapeutics Company Profile
Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Century Therapeutics (IPSC)
- Dollar General Offers Great Prices, but the Stock isn’t a Value
- Jabil Inc.: Blue Chip Tech Stock Pulls Back To Buy Zone
- Should You Bring The Luck Of The Irish To Your Investmets?
- The Big Banks Join Forces to Save First Republic Bank
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.